AstraZeneca, BMS Reluctantly Agree to Medicare Drug Price Negotiation Program

Despite being staunchly opposed to the Inflation Reduction Act’s Drug Price Negotiation Program, AstraZeneca and Bristol Myers Squibb have been left with no choice but to participate, according to Endpoints News.

Under the Inflation Reduction Act (IRA) provisions, companies whose drugs are set to join the first round of drug price negotiations have until Oct. 1 to signify whether they are participating or not. AstraZeneca will negotiate for its type 2 diabetes therapy Farxiga (dapagliflozin), while BMS will discuss the prices for its blood thinner Eliquis (apixaban).